{"id":"octa-c1-inh","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis / thromboembolic events"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL3649602","moleculeType":"Small molecule","molecularWeight":"354.84"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"C1-inhibitor is a serine protease inhibitor that regulates the classical complement pathway and contact system (kallikrein-kinin pathway). Deficiency or dysfunction of C1-INH leads to uncontrolled activation of these cascades, resulting in excessive bradykinin production and angioedema. OCTA-C1-INH restores normal inhibitory control, preventing acute attacks and reducing swelling episodes.","oneSentence":"OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:53.834Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction"}]},"trialDetails":[{"nctId":"NCT06361537","phase":"PHASE3","title":"Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks","status":"RECRUITING","sponsor":"Octapharma","startDate":"2024-04-30","conditions":"Acute Hereditary Angio Edema","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"OCTA-C1-INH","genericName":"OCTA-C1-INH","companyName":"Octapharma","companyId":"octapharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"OCTA-C1-INH is a recombinant C1-esterase inhibitor that replaces or augments deficient or dysfunctional C1-inhibitor protein to prevent excessive complement and contact system activation. Used for Hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}